URMC Welcomes New Chief of Hematology/Oncology

The University of Rochester Medical Center has tapped innovative and respected oncologist Jonathan Friedberg, M.D., to serve as chief of the Division of Hematology/Oncology of the Department of Medicine and the James P. Wilmot Cancer Center.

“Dr. Friedberg’s novel research and leadership within the lymphoma field makes him an excellent choice for chief of Hematology/Oncology,” said Mark B. Taubman, M.D., the Charles E. Dewey Professor of Medicine and chair of the Department of Medicine. “As chief of hematology/oncology, Dr. Friedberg will have the opportunity to grow the clinical enterprise, expand our clinical research programs and set new standards in patient care.”

Friedberg, associate professor of Medicine and director of hematological malignancies clinical research at the Wilmot Cancer Center, has been on the faculty since 2002. He is a national leader in lymphoma care and research. He takes over the position from Richard I. Fisher, M.D., director of the Wilmot Cancer Center.

His research interests focus on development of novel therapies for patients with lymphoma. Most recently, he received the Scholar in Clinical Research Award from the Leukemia & Lymphoma Society for his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma.

Friedberg also plays a lead role in the Wilmot Cancer Center’s Specialized Program of Research Excellence, a prestigious National Cancer Institute-funded program to foster translational research. He is leading the clinical trials program designed to study new therapies for lymphomas.

For more information, please click here.